United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $590.59, for a total transaction of $5,610,605.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $23,926,572.67. The trade was a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $564.81 on Friday. The stock has a market capitalization of $24.76 billion, a price-to-earnings ratio of 20.24, a price-to-earnings-growth ratio of 1.66 and a beta of 0.75. The business has a 50-day moving average of $504.78 and a 200 day moving average of $477.55. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm earned $6.19 EPS. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Wells Fargo & Company lifted their target price on United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a report on Tuesday. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $586.00.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in United Therapeutics during the 4th quarter worth about $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase‑3 Tyvaso (IPF) results met the study’s key endpoint, a material clinical success that supports revenue upside and longer‑term product expansion for United Therapeutics. This is the primary bullish catalyst behind the recent run‑up. United Therapeutics Is Up After Positive Tyvaso Data
• Positive Sentiment: Multiple sell‑side analysts have reacted favorably: HC Wainwright keeps a Buy and $660 target while tweaking quarterly EPS estimates (raising Q3, trimming Q1/Q2 modestly), and other brokers issued bullish notes/upgrades — supporting a higher near‑term valuation band. HC Wainwright Analyst Says Stock Expected to Rise
• Neutral Sentiment: Options activity is unusually high, suggesting traders are positioning around recent news and earnings risk; this can amplify intraday moves but is not a directional fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage pieces and valuation analysis are appearing (assessments of Tyvaso’s impact on valuation); these shape investor expectations but don’t alter the underlying clinical win. Assessing United Therapeutics Valuation After Tyvaso Results
• Negative Sentiment: Insider selling: CEO Martine Rothblatt, EVP Paul Mahon and CFO James Edgemond all sold multi‑thousand share blocks in late March/early April (sales executed under Rule 10b5‑1 plans). The size and timing of these sales (millions of dollars each) can be interpreted as near‑term negative pressure or signal profit‑taking despite being pre‑arranged. Rothblatt SEC Filing (Example)

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.